STCube

STCube OCF Margin

The Operating Cash Flow Margin of STCube (052020.KQ) as of Oct 24, 2026 is -283.15 %. In the previous year, Operating Cash Flow Margin was -206.43 % — a change of 37.16% (lower).

OCF Margin

-283.15 %

YoY

37.16%

Last updated:

Operating Cash Flow Margin of STCube is 2025 -283.15 % . Operating Cash Flow Margin of STCube was 2024 -206.43 % . It decreases by 37.16% lower compared to the previous year.

The STCube OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-56.92 KRW
Jan 1, 2019
-1.11 KRW
Jan 1, 2020
-101.68 KRW
Jan 1, 2021
-216.36 KRW
Jan 1, 2022
-255.32 KRW
Jan 1, 2023
-422.38 KRW
Jan 1, 2024
-206.43 KRW
Jan 1, 2025
-283.15 KRW
The STCube OCF Margin history
YEAROCF MarginYoY
-283.15 %+37.16%
-206.43 %-51.13%
-422.38 %+65.43%
-255.32 %+18.01%
-216.36 %+112.77%
-101.68 %+9,061.85%
-1.11 %-98.05%
-56.92 %-57.68%
-134.52 %-438.49%
39.74 %-144.57%
-89.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Operating Cash Flow Margin of STCube is -283.15 % in 2025.

Operating Cash Flow Margin of STCube changed from -206.43 % to -283.15 %, representing a 37.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin STCube since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — STCube

All Key Metrics — STCube